X4 Pharmaceuticals (XFOR) Current Assets (2017 - 2025)

X4 Pharmaceuticals has reported Current Assets for 9 years, with the latest figure at $261.6 million in Q4 2025.

• For the quarter ending Q4 2025, Current Assets rose 133.19% year-over-year to $261.6 million; the trailing twelve-month figure through Dec 2025 stood at $261.6 million (up 133.19% YoY), and the FY2025 full-year result was $261.6 million, up 133.19% from the prior year.
• Current Assets for Q4 2025 stood at $261.6 million, up from $132.8 million in the prior quarter.
• The five-year high for Current Assets was $261.6 million in Q4 2025, with the low at $52.6 million in Q2 2022.
• Historically, Current Assets has averaged $116.2 million across 5 years, with a median of $106.8 million in 2021.
• Annual changes were most pronounced in 2023 — Current Assets surged 180.78% — and 2025, when it plunged 58.42%.
• X4 Pharmaceuticals' Current Assets stood at $87.9 million in 2021, then surged by 46.43% to $128.7 million in 2022, then declined by 5.13% to $122.1 million in 2023, then dropped by 8.11% to $112.2 million in 2024, then soared by 133.19% to $261.6 million in 2025.
• The last three Current Assets figures came in at $261.6 million (Q4 2025), $132.8 million (Q3 2025), and $72.9 million (Q2 2025), per Business Quant data.